Table 3

Outcomes of anti-Jo1 patients with antisynthetase syndromea
Outcomes Data, n (%)
Resolution 13 (15.1%)
Improvement 55 (63.9%)
Deterioration 18 (20.9%)
ASS course
 Monocyclic 1 (1.2%)
 Chronic continuous 56 (65.1%)
Recurrences
 During tapering of high-dose steroids 5 (5.8%)
 During tapering of low-dose steroids 69 (80.2%)
 Off treatment 1 (1.2%)
 Mortality 10 (11.6%)

aASS: antisynthetase syndrome.

Marie et al.

Marie et al. Arthritis Research & Therapy 2013 15:R149   doi:10.1186/ar4332

Open Data